Anti-CGRP antibody improves work productivity in patients with treatment-resistant migraine

For patients with migraine that does not respond to standard preventive medication, a new analysis shows that treatment with a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) may improve work productivity and activity.

“Migraine is associated with reduced work productivity and activity impairment, which is even higher among patients who are eligible for preventive therapy but did not receive benefit from prior preventive therapy,” according to Dr David Garcia-Azorin of the University Clinical Hospital of Valladolid, Spain.

As part of a randomized trial, Dr Garcia-Azorin and colleagues assessed changes in productivity and activity in 462 patients with episodic or chronic migraine and failure of 2-4 prior therapies. Patients were treated with anti-CGRP therapy galcanezumab or placebo for 3 months.